Skip to main content
. 2016 Jan 18;68(2):118–127. doi: 10.1016/j.ihj.2015.07.027

Table 2.

CV risk factors, characteristics, treatment received, and outcome in STEMI and NSTEMI ACS population.

Characteristics Overall ACS group STEMI Group NSTEMI/Unstable angina Group p value
CV risk factors
 Self-reported hypertension 2510 (43.4%) 986 (37.1%) 1524 (48.4%) 0.001
 Self-reported diabetes 1022 (17.7%) 426 (16.1%) 596 (19.0%) 0.01
 Tobacco smokers (yes) % 3658 (62.9%) 1834 (69.7%) 1823 (58.1%) 0.0001
 Sedentary (yes) % 1716 (29.7%) 746 (28.3%) 970 (30.9%) 0.03
 BMI status 4953 (24.0 ± 4.2) 2230 (23.6 ± 4.1) 2720 (24.4 ± 4.2) 0.001
 BMI < 19.9 960 (18.4%) 487 (20.7%) 473 (16.5%) 0.0001
 BMI 20–24.9 2411 (46.2%) 1130 (48.0%) 1281 (44.6%)
 BMI 25–29.9 1443 (27.6%) 596 (25.3%) 847 (29.5%)
 >30 408 (7.8%) 140 (5.9%) 268 (9.3%)
 Past H/O MI 420 (7.2%) 111 (4.2%) 309 (9.8%) 0.01
 Past H/O CABG 52 (0.9%) 7 (0.3%) 45 (1.4%) 0.01
 Past H/O PCI 86 (1.5%) 16 (0.6%) 70 (2.2%) 0.1
Clinical characteristics
 Tachycardia 985 (21.2%) 482 (21.8%) 503 (20.7%) 0.02
 Hypotension 577 (11.7%) 383 (16.1%) 245 (9.4%) 0.001
 Killip Class 111/1V 639 (11.0%) 353 (13.4%) 286 (9.0%) 0.001
 A Fib 5 (0.1%) 3 (0.1%) 2 (0.1%) 0.5
 VT/VF 50 (0.9%) 30 (1.4%) 20 (0.6%) 0.04
 CHB 246 (4.7%) 145 (6.0%) 101 (3.5%) 0.0001
 Stress hyperglycemia (FBS > 126) 1253 (46.3%) 524 (44.1%) 729 (48.1%) 0.04
 Trop T positive 2309 (40.3%) 1133 (43.0%) 1176 (37.8%)
Treatment
 ASA 5796 (100%) 2634 (100%) 3162 (100%)
 Clopidogrel 5796 (100%) 2634 (100%) 3162 (100%)
 Statin 5650 (97.3%) 2579 (97.7%) 3071 (97.1%) 0.5
 B Blocker 4706 (81.1%) 2017 (76.4%) 2689 (85.0%) 0.001
 ACE inhibitor/ARB 4716 (82.5%) 2035 (78.5%) 2681 (86.0%) 0.01
 Thrombolytic therapy 948 (16.3%) 939 (35.6%) 9 (0.3%)
 PCI 37 (0.6%) 25 (0.9%) 12 (0.4%) 0.01
Outcome
 Death 442 (7.6%) (6.9–8.3%) 284 (10.8%) 158 (5.0%) 0.0001
 Bleeding 55 (1.0%) 33 (1.4%) 22 (0.8% 0.07
 Post-MI angina 125 (2.4%) 68 (2.8%) 57 (2.0%) 0.054
 Cardiogenic shock 455 (10.2%) 280 (13.0%) 175 (7.6%) 0.001